Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse

PHASE3CompletedINTERVENTIONAL
Enrollment

976

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

January 31, 2009

Study Completion Date

June 30, 2012

Conditions
Ovarian CancerFallopian Tube Cancer
Interventions
DRUG

Pegylated liposomal doxorubicin

30 mg/m² every 4 weeks during 6 cycles or until progression

DRUG

Carboplatin

AUC 5 every 3/4 weeks during 6 cycles or until progression

DRUG

Paclitaxel

175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression

Trial Locations (1)

75004

Hôpital Hôtel Dieu, Paris

All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

collaborator

Arbeitsgemeinschaft Gynaekologische Onkologie Austria

OTHER

collaborator

AGO Study Group

OTHER

collaborator

Australia New Zealand Gynaecological Oncology Group

OTHER

collaborator

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

collaborator

NCIC Clinical Trials Group

NETWORK

collaborator

NSGO

UNKNOWN

lead

ARCAGY/ GINECO GROUP

OTHER